[Progress in 2008 for acid related diseases]

P Jornod1, D Vouillamoz, F Viani

  • 1Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|March 11, 2009
PubMed

Insights

Proton pump inhibitors (PPIs) remain the primary treatment for reflux disease and NSAID-induced symptoms. Sequential therapy is now a first-line option for H. pylori infections.

Area of Science:

  • Gastroenterology
  • Pharmacology

Context:

  • Review of current treatment guidelines for gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) infection.
  • Evaluation of the role of proton pump inhibitors (PPIs) in managing NSAID-induced gastroduodenal lesions and dyspeptic symptoms.

Purpose:

  • To summarize the current evidence-based treatment strategies for reflux disease and H. pylori infection.
  • To clarify the appropriate use of PPIs in patients undergoing NSAID treatment.

Summary:

  • Proton pump inhibitors (PPIs) are the first-line treatment for reflux disease, with surgery as a second-line option. Endoscopic anti-reflux procedures require further controlled studies.
  • Sequential treatment is now a recognized first-line therapy for H. pylori infection, alongside classic triple therapy.
  • PPIs effectively prevent gastroduodenal lesions and treat NSAID-induced dyspepsia. Preventive PPIs are recommended for patients over 65 or those with risk factors during NSAID therapy.

Impact:

  • Provides clinicians with updated, evidence-based recommendations for managing common gastrointestinal conditions.
  • Optimizes the use of PPIs, potentially reducing unnecessary prescriptions and healthcare costs.
  • Highlights the evolving landscape of H. pylori treatment strategies.

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Peptic Ulcer Disease I: Introduction01:25

Peptic Ulcer Disease I: Introduction

Peptic ulcer disease (PUD) involves breaks in the gastrointestinal tract's mucosal lining, primarily in the stomach and duodenum, with less frequent occurrences in the lower esophagus or near the pylorus.Ulcers can be acute or chronic. Acute ulcers are short-lived with minimal inflammation and heal quickly after the irritant is removed. Chronic ulcers persist, may recur, and often cause scarring due to ongoing tissue damage. Superficial erosions affect only the mucosal layer and are called...